Previous 10 | Next 10 |
home / stock / glpgf / glpgf news
Mechelen, Belgium; 19 December 2023, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the first patient has been dosed in PAPILIO-1, the Phase 1/2 study to evaluate the safety, efficacy, and feasibility of our seven-day vein-to-vein, point-of-care manufactured BCMA CAR-T...
Additional safety and efficacy data further support potential of innovative, decentralized approach to CAR-T manufacturing and transformational impact on patients with severe hematologic cancers Two poster presentations include recent data updates and additional data not included in the A...
Mechelen, Belgium; 6 December 2023, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will host a Key Opinion Leader (KOL) event during the 65th ASH Annual Meeting & Exposition in San Diego, CA, on Sunday, December 10, 2023, from 11:00 am PST to 12:30 pm PST. The i...
2023-11-21 11:00:00 ET Summary Galapagos pivots to CAR-T therapy, divesting Jyseleca; faces clinical, market risks amidst investor skepticism. Revenue up 9% YOY; operating losses reduced; strong cash reserve at $4.2B; net profit achieved. Negative enterprise value and underper...
2023-11-05 09:14:09 ET Galapagos NV (GLPG) Q3 2023 Earnings Conference Call November 3, 2023 08:00 AM ET Company Participants Sofie Van Gijsel - Head, IR Paul Stoffels - CEO, Chairman, Interim Head, R&D Thad Huston - CFO & COO Jeevan Shetty - Head of ...
First nine months 2023 key financials: Group revenues of €448.9 million Jyseleca® net sales of €82.1 million Cash and current financial investments of €3.8 billion at 30 September 2023 Full year 2023 net Jyseleca® sales guidance of ...
Transaction would enable Galapagos to realize considerable annualized savings and accelerate its pipeline focused on developing transformational medicines Aims to preserve the Jyseleca® (filgotinib) business and a significant number of positions Galapagos plans to streamline ...
Mechelen, Belgium; 1 9 September 2023, 22:01 CET ; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that during its meeting of 19 September 2023 , the Board of Directors appointed Mr. Simon Sturge as N o n- E ...
GLPG3667 is an investigational, novel, oral, reversible, and selective tyrosine kinase 2 (TYK2) inhibitor GLPG3667 is currently in development for the treatment of inflammatory and auto-immune diseases and is in Phase 2 for d ermatomyositis Mechelen, Belgium; 28 ...
2023-08-24 10:55:38 ET More on Galapagos Galapagos NV ( GLPG ) Q2 2023 Earnings Call Transcript Galapagos to transfer drug discovery and research activities in France to NovAliX Galapagos stock dips as Jyseleca fails phase 3 trial as induction therapy in Crohn's ...
News, Short Squeeze, Breakout and More Instantly...
Galapagos Genomics Ord Company Name:
GLPGF Stock Symbol:
OTCMKTS Market:
Galapagos Genomics Ord Website:
Mechelen, Belgium; June 14, 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will present encouraging new data from the ongoing Phase 1/2 ATALANTA-1 study of CD19 CAR-T candidate, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma (R/R NHL) at the annual Euro...
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next generation MAGE-A4 TCR T-cell therapy) produced on Galapagos’ decentralized manufacturing platform in patients with head & neck cancer Uza-cel has shown enc...
BCA's national network of blood centers will provide decentralized manufacturing services for Galapagos' CAR-T product candidates, close to cancer treatment centers Collaboration enables rapid deployment of Galapagos' decentralized CAR-T platform across the U.S., improving patient access ...